On another note6 Oct 2018 13:46
Nothing to do with my last message reading the full statement on the faron site it states that the traumakine may also be usefully in other conditions so is not just for one condition and on going tests will be carried out for these other conditions. This would result in multi use of it and would not necessarily need to pass the texts which it has been primarily made for so my conclusion is that the drug having multi uses is far more valuable in the future than the general consensus suggests therefore in the long term it will be a win even if it is only partially successful for its primary use. For me that is a big plus. As for our other projects they all ad up to a bigger pie in the future.